Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Entrada Therapeutics (NASDAQ: TRDA) has granted 23,820 restricted stock units (RSUs) to six new non-executive employees under its 2025 Inducement Equity Plan, effective June 1, 2025. The grants were approved by the Board's Compensation Committee as a material inducement for employment, complying with Nasdaq Rule 5635(c)(4). The vesting schedule includes 25% vesting after one year, followed by quarterly vesting of 6.25% on March 1, June 1, September 1, and December 1 of subsequent years, contingent on continued employment. The RSUs are governed by the Inducement Plan terms approved in March 2025 and individual award agreements.

Positive

• RSU grants help attract and retain new talent
• Structured vesting schedule helps ensure employee retention

Negative

• Potential dilution for existing shareholders
• Additional compensation expenses for the company

BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units (“RSUs”) to six newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2025. The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest quarterly thereafter on each subsequent vesting date, with such vesting dates of March 1, June 1, September 1, and December 1 of each subsequent year, in each case, subject to each employee’s continuous service with the Company through each vesting date. The RSUs are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2025 and the terms and conditions of award agreements covering the grants.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Investor and Media Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com 

FAQ

How many RSUs did Entrada Therapeutics (TRDA) grant to new employees in June 2025?

Entrada Therapeutics granted 23,820 RSUs to six newly-hired non-executive employees.

What is the vesting schedule for Entrada Therapeutics' June 2025 RSU grants?

25% vests after one year, followed by 6.25% quarterly vesting on March 1, June 1, September 1, and December 1 of subsequent years.

When was Entrada Therapeutics' 2025 Inducement Equity Plan approved?

The Inducement Plan was approved by the Company's Board of Directors in March 2025.

How many new employees received RSU grants from Entrada Therapeutics in June 2025?

Six newly-hired non-executive employees received RSU grants.